Candida albicans binds and utilizes human complement inhibitors, such as C4b-binding protein (C4BP), Factor H, and FHL-1 for immune evasion. Here, we identify Candida pH-regulated antigen 1 (Pra1) as the first fungal C4BP-binding protein.Recombinant Pra1 binds C4BP, as shown by ELISA and isothermal titration calorimetry, and the Pra1-C4BP interaction is ionic in nature. The Pra1 binding domains within C4BP were localized to the complement control protein domain 4 (CCP4), CCP7, and CCP8. C4BP bound to Pra1 maintains complementinhibitory activity. C4BP and Factor H bind simultaneously to Candida Pra1 and do not compete for binding at physiological levels. A Pra1-overexpressing C. albicans strain, which had about 2-fold Pra1 levels at the surface acquired also about 2-fold C4BP to the surface, compared with the wild type strain CAI4. A Pra1 knock-out strain showed ϳ22% reduced C4BP binding. C4BP captured by C. albicans from human serum inhibits C4b and C3b surface deposition and also maintains cofactor activity. In summary, Candida Pra1 represents the first fungal C4BP-binding surface protein. Pra1, via binding to C4BP, mediates human complement control, thereby favoring the immune and complement evasion of C. albicans.Candida albicans is a dimorphic human pathogenic fungus, which causes superficial as well as systemic infections most frequently in patients undergoing immunosuppressive therapy or long term catheterization (1). Despite currently applied antifungal therapies, both mortality and morbidity mediated by C. albicans are still unacceptably high (2-4). Therefore, new prophylactic and therapeutic strategies are needed to prevent fungal spreading and tissue damage. The identification of novel yeast virulence factors that contribute to pathogenicity is necessary for approaching new strategies to fight and interfere with Candida infections. In this study, we aimed to identify surface proteins that are central for C. albicans innate immune escape.The human complement system forms the first defense line of innate immunity. Upon infection, microbes are immediately attacked by this highly efficient human immune system (5, 6). Complement can be activated via three major pathways. The classical pathway (CP) 2 is mainly induced by antibodies bound to target structures or by C-reactive protein, and the lectin pathway (LP) is activated by binding of mannose-binding lectin or ficolins to mannan-containing structures on surfaces (7-9). The alternative pathway is initiated spontaneously and continuously by randomly generated C3b, and activated C3b can bind directly to any surface and initiate an amplification loop of the alternative pathway (10, 11).Progression of the complement cascade is controlled by fluid phase inhibitors, which are distributed in plasma and body fluid, or surface-bound inhibitors. These inhibitors include C4BP, a 570-kDa plasma glycoprotein, which is the major fluid phase CP and LP inhibitor (12), as well as Factor H and FHL-1 (Factor H-like protein 1), which are the major fluid phase alternative path...